Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$145.08

-1.9 (-1.29%)

10:54
10/04/18
10/04
10:54
10/04/18
10:54

Sarepta micro-dystrophin gene therapy update continues to impress, says Janney Montgomery Scott

Janney Montgomery Scott analyst Yun Zhong believes the three-month muscle biopsy data from the fourth patient and the functional results from all four patients that Sarepta reported at the Annual Congress of the World Muscle Society provide "strong" additional evidence to support a favorable clinical profile of the micro-dystrophin gene therapy program. The analyst notes that management has requested a meeting with the FDA and he continues to expect the agency to be supportive for an expedited regulatory pathway. Upon FDA feedback, patient dosing in the pivotal study could begin in Q4 of 2018/Q1 of 2019, he contends. Additionally, Zhong expects the initial data from the LGMD2E gene therapy program to be positive, based on a readthrough from the micro-dystrophin program. He reiterates a Buy rating and $200 fair value estimate on the shares.

  • 04

    Oct

SRPT Sarepta
$145.08

-1.9 (-1.29%)

10/04/18
NEED
10/04/18
NO CHANGE
NEED
Needham impressed with Sarepta micro-dystrophin gene therapy data
Needham analyst Chad Messer reiterated a Buy rating and $196 price target after updated data from Sarepta's micro-dystrophin gene therapy program was presented at the World Muscle Society Congress. The data indicated that all four patients showed "impressive improvements on multiple functional measures," and Messer noted that Sarepta has already requested an FDA meeting and expects to initiate a pivotal study by the end of this year.
10/04/18
FBCO
10/04/18
NO CHANGE
Target $189
FBCO
Outperform
Sarepta price target raised to $189 from $178 at Credit Suisse
10/04/18
PIPR
10/04/18
NO CHANGE
Target $189
PIPR
Overweight
Sarepta price target raised to $189 from $168 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics to $189 after the company presented new Phase I/II microdystrophin gene therapy data for a four Duchenne muscular dystrophy boy and updated data for three boys. The analyst views the data for the fourth boy as "robust"and says microdystrophin is safe with durable gene expression. He believes micro-dystrophin geneRx could address up to 70% of DMD boys and gain accelerated approval in 2020. Tenthoff reiterates an Overweight rating on shares of Sarepta.
10/04/18
MSCO
10/04/18
NO CHANGE
Target $163
MSCO
Overweight
Morgan Stanley sees Sarepta trading up over 10% on gene therapy data
Morgan Stanley analyst Matthew Harrison said the updated data presented by Sarepta at the World Muscle meeting on its gene therapy program was "well above" his expectations and that the consistency in the program to a fourth child increases his confidence. He sees the directional consistency in the data, even if excluding the fourth patient's "exceptional response," and the significant increase in NSAA as very supportive of a robust functional impact, Harrison tells investors. The analyst, who said he expects Sarepta shares to trade up by over 10% on the data, keeps an Overweight rating on the stock with a $163 price target. In pre-market trading, Sarepta shares are up about 3.5% to $152.50.

TODAY'S FREE FLY STORIES

13:45
08/21/19
08/21
13:45
08/21/19
13:45
General news
Breaking General news story  »

FOMC Minutes to be…

AFL

Aflac

$49.66

-2.2 (-4.24%)

13:38
08/21/19
08/21
13:38
08/21/19
13:38
Periodicals
Aflac reiterates review being done of Post channel sales, Bloomberg says »

Aflac reiterated that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,823.96

21.88 (1.21%)

, WMT

Walmart

$112.15

0.03 (0.03%)

13:37
08/21/19
08/21
13:37
08/21/19
13:37
Periodicals
Amazon opens 'largest campus yet' in south Indian city, Bloomberg says »

According to an earlier…

AMZN

Amazon.com

$1,823.96

21.88 (1.21%)

WMT

Walmart

$112.15

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 25

    Sep

  • 27

    Oct

  • 13

    Nov

  • 14

    Nov

CBL

CBL & Associates

$0.86

0.022 (2.62%)

13:32
08/21/19
08/21
13:32
08/21/19
13:32
Hot Stocks
CBL Properties to pursue measures to cure NYSE rule non-compliance »

CBL Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
08/21/19
08/21
13:25
08/21/19
13:25
Conference/Events
The Food & Drug Law Institute to hold a webinar »

Anthony Anscombe, Partner…

13:25
08/21/19
08/21
13:25
08/21/19
13:25
Conference/Events
FOMC releases minutes from July 30-31, 2019 Policy Meeting »

The Federal Open Market…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/21/19
08/21
13:17
08/21/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,195.07

11.64 (0.98%)

, GOOGL

Alphabet Class A

$1,196.08

11.82 (1.00%)

13:16
08/21/19
08/21
13:16
08/21/19
13:16
Hot Stocks
YouTube Premium users can now listen directly within Waze app »

In an earlier blog post,…

GOOG

Alphabet

$1,195.07

11.64 (0.98%)

GOOGL

Alphabet Class A

$1,196.08

11.82 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/21/19
08/21
13:16
08/21/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHC

Bausch Health

$22.31

1.05 (4.94%)

13:06
08/21/19
08/21
13:06
08/21/19
13:06
Hot Stocks
Bausch Health trades up after VP Humphries buys over $650K in shares »

Bausch Health VP William…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

FB

Facebook

$185.03

1.27 (0.69%)

, TWTR

Twitter

$42.65

0.355 (0.84%)

13:05
08/21/19
08/21
13:05
08/21/19
13:05
On The Fly
#SocialStocks: New 'Off-Facebook Activity' tool, Argus upgrades Pinterest »

Welcome to…

FB

Facebook

$185.03

1.27 (0.69%)

TWTR

Twitter

$42.65

0.355 (0.84%)

PINS

Pinterest

$36.40

2.05 (5.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

ALXN

Alexion

$113.91

2.49 (2.23%)

13:05
08/21/19
08/21
13:05
08/21/19
13:05
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 02

    Oct

  • 19

    Oct

VIOT

Viomi Technology

$9.00

-0.27 (-2.91%)

12:57
08/21/19
08/21
12:57
08/21/19
12:57
Initiation
Viomi Technology initiated at Needham »

Viomi Technology assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

MAS

Masco

$40.58

0.95 (2.40%)

, GWW

Grainger

$276.25

4.29 (1.58%)

12:57
08/21/19
08/21
12:57
08/21/19
12:57
Periodicals
Masco trades higher after Bloomberg report on bidders for cabinet-making unit »

Late in the trading…

MAS

Masco

$40.58

0.95 (2.40%)

GWW

Grainger

$276.25

4.29 (1.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 23

    Oct

PFPT

Proofpoint

$117.13

5.14 (4.59%)

12:55
08/21/19
08/21
12:55
08/21/19
12:55
Conference/Events
Proofpoint participates in a conference call with Wedbush »

Software Analyst Koenig…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 28

    Aug

  • 28

    Aug

  • 05

    Sep

  • 10

    Oct

  • 15

    Oct

  • 13

    Nov

  • 12

    Dec

  • 16

    Dec

BLK

BlackRock

$420.88

2.92 (0.70%)

12:54
08/21/19
08/21
12:54
08/21/19
12:54
Periodicals
BlackRock funds get approval to acquire stake in Cofense, WSJ reports »

The Committee on Foreign…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

GS

Goldman Sachs

$200.90

0.98 (0.49%)

12:52
08/21/19
08/21
12:52
08/21/19
12:52
Periodicals
Goldman Sachs studying sale of Safe-Guard Products unit, Reuters reports »

Goldman Sachs is working…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

JNJ

Johnson & Johnson

$131.60

1.03 (0.79%)

, LLY

Eli Lilly

$111.90

0.94 (0.85%)

12:26
08/21/19
08/21
12:26
08/21/19
12:26
Periodicals
HHS appeals ruling over pharma prices in TV ads, STAT News reports »

The U.S. Department of…

JNJ

Johnson & Johnson

$131.60

1.03 (0.79%)

LLY

Eli Lilly

$111.90

0.94 (0.85%)

MRK

Merck

$87.16

1.5 (1.75%)

PFE

Pfizer

$35.04

0.42 (1.21%)

SNY

Sanofi

$43.35

0.76 (1.78%)

AZN

AstraZeneca

$45.59

0.97 (2.17%)

GSK

GlaxoSmithKline

$40.85

0.59 (1.47%)

NVS

Novartis

$90.50

1.43 (1.61%)

RHHBY

Roche

$0.00

(0.00%)

BMY

Bristol-Myers

$47.65

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 03

    Sep

  • 04

    Sep

  • 06

    Sep

  • 06

    Sep

  • 09

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 19

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 01

    Oct

  • 02

    Oct

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 04

    Nov

NVRO

Nevro

$84.55

1.57 (1.89%)

12:25
08/21/19
08/21
12:25
08/21/19
12:25
Conference/Events
Nevro participates in a conference call with SVB Leerink »

SVB Leerink holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 26

    Aug

  • 09

    Sep

VG

Vonage

$13.53

0.185 (1.39%)

, FIVN

Five9

$64.11

1.63 (2.61%)

12:25
08/21/19
08/21
12:25
08/21/19
12:25
Conference/Events
Stephens Cloud Infrastructure Analyst to hold Analyst/Industry conference call »

Enterprise & Cloud…

VG

Vonage

$13.53

0.185 (1.39%)

FIVN

Five9

$64.11

1.63 (2.61%)

TWLO

Twilio

$132.21

5.32 (4.19%)

WORK

Slack Technologies

$31.07

0.575 (1.89%)

AMZN

Amazon.com

$1,824.00

21.92 (1.22%)

MSFT

Microsoft

$138.82

1.57 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 04

    Sep

  • 05

    Sep

  • 10

    Sep

  • 27

    Oct

  • 13

    Nov

AAPL

Apple

$213.25

2.9 (1.38%)

, FB

Facebook

$185.05

1.29 (0.70%)

12:21
08/21/19
08/21
12:21
08/21/19
12:21
Periodicals
Trump says relationship better with Apple CEO than other tech execs, CNBC says »

CNBC's Eamon Javers…

AAPL

Apple

$213.25

2.9 (1.38%)

FB

Facebook

$185.05

1.29 (0.70%)

AMZN

Amazon.com

$1,824.53

22.45 (1.25%)

GOOGL

Alphabet Class A

$1,195.80

11.54 (0.97%)

GOOG

Alphabet

$1,195.03

11.6 (0.98%)

TWTR

Twitter

$42.78

0.485 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
08/21/19
08/21
12:17
08/21/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IGLD

Internet Gold

$24.80

-0.75 (-2.94%)

12:16
08/21/19
08/21
12:16
08/21/19
12:16
Hot Stocks
Internet Gold announces receipt of Nasdaq non-compliance notice »

Internet Gold announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$8.32

-0.07 (-0.83%)

12:16
08/21/19
08/21
12:16
08/21/19
12:16
Hot Stocks
NY AG files lawsuit against EPA over GE Hudson River PCB cleanup »

New York Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 30

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
08/21/19
08/21
12:16
08/21/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.